Richard S. Ginsberg

First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

Rob Roy MacGregor, Jean Boyer, Kenneth E. Ugen et al. · The Journal of Infectious Diseases · 1998 · 640 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

Lawrence D. Mayer, Linda C.L. Tai, Dicken S. C. Ko et al. · PubMed · 1989 · 355 citations

Pharmacy, Biochemistry, Pharmacology +17

Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients

Lawrence D. Mayer, Linda C.L. Tai, Marcel B. Bally et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 1990 · 244 citations

Pharmacy, Pharmaceutics, Pharmacokinetics +11

Vaccination of Seronegative Volunteers with a Human Immunodeficiency Virus Type 1<i>env/rev</i>DNA Vaccine Induces Antigen‐Specific Proliferation and Lymphocyte Production of β‐Chemokines

Jean Boyer, Adam D. Cohen, Suzanne Vogt et al. · The Journal of Infectious Diseases · 2000 · 156 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

J. Wayne Cowens, Patrick J. Creaven, William R. Greco et al. · PubMed · 1993 · 136 citations

Medicine, Pharmacokinetics, Pharmacology +17